Mats Jerkeman
11 – 20 of 203
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2025
-
Mark
Validation of POD24 as a robust early clinical indicator of poor survival in mantle cell lymphoma from 1280 patients on clinical trials, a LYSA study
- Contribution to journal › Article
-
Mark
Hypogammaglobulinemia at Diagnosis is Associated With Inferior Survival and Higher Risk of Infections in Diffuse Large B Cell Lymphoma
- Contribution to journal › Article
-
Mark
Limited stage mantle cell lymphoma : A real-world study of primary treatment and prognosis in Sweden 2006–2018
- Contribution to journal › Letter
-
Mark
Impact of immunochemotherapy regimens on outcomes of patients with primary mediastinal B-cell lymphoma in the IELSG37 trial
(2025) In Blood
- Contribution to journal › Article
-
Mark
Peripheral T- and natural killer-cell lymphomas : ESMO–EHA Clinical Practice Guideline for diagnosis, treatment and follow-up ☆
- Contribution to journal › Article
- 2024
-
Mark
Outcomes for patients with secondary CNS involvement in relapsed/refractory diffuse large B-cell lymphoma and estimation of eligibility for CAR T-cell therapy
- Contribution to journal › Letter
-
Mark
MRD-driven treatment with venetoclax-R2 in mantle cell lymphoma : the Nordic Lymphoma Group MCL7 VALERIA trial
- Contribution to journal › Article
-
Mark
Primary central nervous system lymphomas : EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆
- Contribution to journal › Article
-
Mark
Primary central nervous system lymphomas : EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
- Contribution to journal › Article
-
Mark
Tattoos as a risk factor for malignant lymphoma: a population-based case–control study
- Contribution to journal › Article
